NCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT02921256 2025-12-04
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02008656 2025-08-27
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05965531 2025-04-29
TASLARC
Sun Yat-sen University
Phase 2 Recruiting
NCT04380337 2025-02-25
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02864849 2021-07-23
Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT04340401 2020-07-09
Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01729923 2018-01-16
ADAPT
University of Washington
Phase 2 Terminated
NCT01148056 2017-02-15
Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT01340508 2011-04-22
Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer
National University Hospital, Singapore
Phase 2 Unknown